After all, the Johnson & Johnson brand is used by more people and receives more attention. Moreover, Johnson & Johnson's products are mainly used on humans, so they are also more concerned about. If there are any harmful substances, what will cause danger to humans. Nowadays, people pay more attention to health and safety. Moreover, there have been many examples of casualties in Johnson & Johnson, so people have to pay more attention to it.
Pfizer and Johnson & Johnson, one based in New York and the other in New Jersey, are both domestic pharmaceutical companies in the United States and have frequently quarreled in the U.S. market. Pfizer has filed a lawsuit against Johnson & Johnson, accusing Johnson & Johnson of blocking access to competing biosimilars of its arthritis treatment Remicade, preventing health insurers, hospitals and clinics from offering Pfizer's lower-priced biosimilars.
Remicade is the world’s best-selling anti-inflammatory drug, primarily used to treat chronic diseases such as rheumatoid arthritis, plaque psoriasis and Crohn’s disease. In 2014, global sales reached US$9.24 billion, ranking third on the list of "The 25 Best-Selling Drugs in the World in 2014".
Pfizer filed the lawsuit in federal court in Philadelphia. The lawsuit alleges that Johnson & Johnson's exclusivity contracts forced hospitals and clinics to stop buying Pfizer's biosimilar Inflectra, and that health insurers stopped paying for prescriptions involving Inflectra in order to receive rebates and other benefits. Pfizer is asking the federal district court to invalidate such contracts and order Johnson & Johnson to pay compensation for lost sales.
These two companies are in a state of competition, and they both want to kill each other, so it is normal for the two companies to compete with each other. If one side wins, the benefits they gain are immeasurable.